Equal Access to Therapeutics Act
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Feb 7, 2022)
Equal Access to Therapeutics Act
This bill prohibits using race or ethnicity as a factor in decisions about an individual's access to COVID-19 treatments (e.g., monoclonal antibody therapies).
Specifically, the Department of Health and Human Services (HHS) may not adopt any policy or guidance that allows race or ethnicity to be factored into such decisions. Furthermore, the Secretary of HHS shall be personally liable for the death of any individual who is denied access to COVID-19 treatments pursuant to a prohibited policy or guidance.
The bill also prohibits hospitals or other health care providers that have policies restricting access to COVID-19 treatments based on race or ethnicity from receiving federal funds.
What just happenedFeb 8, 2022
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseFeb 7, 2022
- Feb 8, 2022Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Feb 7, 2022IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Feb 7, 2022IntroReferralIntro-H
Introduced in House
- Feb 7, 2022IntroReferral1000
Introduced in House